Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?

Title: Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Authors: Calogera Claudia Spagnolo; Giuliana Ciappina; Elisa Giovannetti; Andrea Squeri; Barbara Granata; Chiara Lazzari; Giulia Pretelli; Giulia Pasello; Mariacarmela Santarpia
Source: International Journal of Molecular Sciences, Vol 24, Iss 12, p 10119 (2023)
Publisher Information: MDPI AG
Publication Year: 2023
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: non-small cell lung cancer (NSCLC); mesenchymal-epithelial transition (MET); targeted therapy; oncogene; predictive biomarkers; tyrosine kinase inhibitors (TKIs); Biology (General); QH301-705.5; Chemistry; QD1-999
Description: In recent years, we have seen the development and approval for clinical use of an increasing number of therapeutic agents against actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC). Among them, selective inhibitors, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting the mesenchymal–epithelial transition (MET) receptor, have been studied in patients with advanced NSCLC with MET deregulation, primarily due to exon 14 skipping mutations or MET amplification. Some MET TKIs, including capmatinib and tepotinib, have proven to be highly effective in this molecularly defined subgroup of patients and are already approved for clinical use. Other similar agents are being tested in early-stage clinical trials with promising antitumor activity. The purpose of this review is to provide an overview of MET signaling pathways, MET oncogenic alterations primarily focusing on exon 14 skipping mutations, and the laboratory techniques used to detect MET alterations. Furthermore, we will summarize the currently available clinical data and ongoing studies on MET inhibitors, as well as the mechanisms of resistance to MET TKIs and new potential strategies, including combinatorial approaches, to improve the clinical outcomes of MET exon 14-altered NSCLC patients.
Document Type: article in journal/newspaper
Language: English
Relation: https://www.mdpi.com/1422-0067/24/12/10119; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067; https://doaj.org/article/8d5cbcb12fc84ae29f9d20b28638b6dc
DOI: 10.3390/ijms241210119
Availability: https://doi.org/10.3390/ijms241210119; https://doaj.org/article/8d5cbcb12fc84ae29f9d20b28638b6dc
Accession Number: edsbas.6964444B
Database: BASE